<?xml version="1.0" encoding="UTF-8"?>
<p>When a vaccine is intended for widespread use in the general population, conducting the trial in the general population will enhance the generalizability of trial results. However, such trials will be feasible only if the incidence of the disease under study is high enough for a trial of manageable size. A vaccine trial conducted in persons at high risk of exposure, such as serodiscordant couples for a sexually transmitted infection [
 <xref rid="pmed.1002632.ref013" ref-type="bibr">13</xref>] or healthcare workers for a disease transmitted by direct contact [
 <xref rid="pmed.1002632.ref014" ref-type="bibr">14</xref>], is likely to reduce the required sample size and have greater statistical efficiency.
</p>
